Enliven Therapeutics annual return on equity
2020
2021
2023
2024
2025
Enliven Therapeutics Return on Equity (ROE) Growth & History (ELVN)
Enliven Therapeutics's return on equity was −26.95% for fiscal 2025.
View full Enliven Therapeutics company overviewEnliven Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −26.95% | +5.08 pp |
| 2024 | 2024-12-31 | −32.04% | +52.64 pp |
| 2023 | 2023-12-31 | −84.67% | — |
| 2021 | 2021-12-31 | −247.35% | −14.90 pp |
| 2020 | 2020-12-31 | −232.44% | — |
Enliven Therapeutics quarterly return on equity
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −4.82% | +1.71 pp |
| Q1 2026 | 2026-03-31 | −5.18% | +4.37 pp |
| Q4 2025 | 2025-12-31 | −6.34% | +1.41 pp |
| Q3 2025 | 2025-09-30 | −4.18% | +3.63 pp |
| Q2 2025 | 2025-06-30 | −6.52% | −0.12 pp |
| Q1 2025 | 2025-03-31 | −9.54% | −1.48 pp |
| Q4 2024 | 2024-12-31 | −7.75% | −0.12 pp |
| Q3 2024 | 2024-09-30 | −7.81% | −0.12 pp |
| Q2 2024 | 2024-06-30 | −6.41% | −0.55 pp |
| Q1 2024 | 2024-03-31 | −8.07% | +5.65 pp |
| Q4 2023 | 2023-12-31 | −7.63% | — |
| Q3 2023 | 2023-09-30 | −7.68% | — |
| Q2 2023 | 2023-06-30 | −5.86% | — |
| Q1 2023 | 2023-03-31 | −13.72% | — |
| Q4 2021 | 2021-12-31 | −50.70% | −37.84 pp |
| Q3 2021 | 2021-09-30 | −16.61% | −4.25 pp |
| Q2 2021 | 2021-06-30 | −18.73% | −9.08 pp |
| Q1 2021 | 2021-03-31 | −12.82% | +12.79 pp |
| Q4 2020 | 2020-12-31 | −12.86% | — |
| Q3 2020 | 2020-09-30 | −12.36% | — |
| Q2 2020 | 2020-06-30 | −9.65% | — |
| Q1 2020 | 2020-03-31 | −25.61% | — |
Enliven Therapeutics return on equity trends
Over the last five fiscal years, Enliven Therapeutics's return on equity increased from −232.44% to −26.95%, a change of +205.49 percentage points. The latest reported quarter, Q2 2026, shows −4.82%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Enliven Therapeutics source filings ↗